Matrix metalloproteinase-3 serum levels in schizophrenic patients.
Michal OrdakMalgorzata Libman-SokolowskaTadeusz NasierowskiBogna BadyraLeszek KaczmarekElzbieta MuszynskaMagdalena Bujalska-ZadroznyPublished in: International journal of psychiatry in clinical practice (2022)
MMP-3 may be associated with gender, treatment and symptoms in schizophrenic patients.KEY POINTSMMP3 could be used as a potential biomarker for schizophrenia.The level of MMP-3 decreased due to the applied antipsychotic treatment.The higher the level of MMP-3 in a group of people with schizophrenia, the better insight into their disease.